TriangleFostamatinib (NCT06639724)
Fostamatinib trial for Pancreatic Ductal Adenocarcinoma (PDAC) (NCT06639724). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for resectable pancreatic cancer that has not spread, in adults.
The idea: add fostamatinib, a Syk kinase inhibitor currently FDA approved for ITP, to standard chemotherapy given before and after surgery. Patients take it by mouth twice a day for 7 days before chemotherapy, and then during chemotherapy. The main measure is whether surgery is delayed.
This phase 1b trial plans 36 patients. At the University of California, San Diego Moores Cancer Center, Andrew Lowy, listed as study chair, leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.